Extended Versus No Lymph Node Removal During Prostate Surgery
Tests extended lymph node removal during prostate surgery in men with prostate cancer.
Plain-language title generated from the registry record
Registry title: Extended vs. No Pelvic Lymph Node Dissection During Radical Prostatectomy. DISSECTION 2.0.
Key facts
- Where
- Aarau, Basel, Bern, Biel, Chur, Geneva, Lausanne, Liestal, Lucerne, Lugano, Neuchâtel, Sankt Gallen, and Zurich, SwitzerlandSee the 15 sites
Where in Switzerland
- Cantonal Hospital AarauAarau, SwitzerlandTaking people
- University Hospital BaselBasel, SwitzerlandTaking people
- InselspitalBern, SwitzerlandTaking people
- Lindenhof HospitalBern, SwitzerlandTaking people
- Cantonal Hospital BielBiel, SwitzerlandTaking people
- Cantonal Hospital ChurChur, SwitzerlandTaking people
- University Hospital GenevaGeneva, SwitzerlandTaking people
- Centre Hospitalier Universitaire Vaudois (CHUV)Lausanne, SwitzerlandTaking people
- Cantonal Hospital LiestalLiestal, SwitzerlandTaking people
- Cantonal Hospital LuzernLucerne, SwitzerlandTaking people
- Ospedale Regionale di LuganoLugano, SwitzerlandTaking people
- Cantonal Hospital NeuchâtelNeuchâtel, SwitzerlandTaking people
- Cantonal Hospital St GallenSankt Gallen, SwitzerlandTaking people
- Hospital Triemli, ZürichZurich, SwitzerlandTaking people
- University Hospital ZurichZurich, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Basel, Switzerland
- Trial code
- NCT06776172
- Record updated
- 3 July 2025
- Original description
The aim of the DISSECTION 2.0 study is to determine whether extended pelvic lymph node dissection (ePLND) provides a therapeutic benefit for high-risk prostate cancer patients by improving cancer staging and potentially removing micrometastatic disease, ultimately improving their outcomes.Read full original descriptionShow less
Extended Pelvic Lymph Node Dissection vs. No Pelvic Lymph Node Dissection at Radical Prostatectomy in PSMA PET Negative Staged Men: A Multicenter, Randomized Phase III Trial
The aim of the DISSECTION 2.0 study is to determine whether extended pelvic lymph node dissection (ePLND) provides a therapeutic benefit for high-risk prostate cancer patients by improving cancer staging and potentially removing micrometastatic disease, ultimately improving their outcomes.
Inclusion: Age ≥ 18 years and life expectancy >15 years; Any biopsy-proven WHO/ISUP grade groups III-V PCa; High-risk prostate cancer defined as:; Any biopsy-proven WHO/ISUP grade group III-V PCa or; ISUP grade group II and PSA > 20 ng/ml; PSMA-PET: negative staging for regional and distant metastasis; multidisciplinary tumorboard recommendation for radical prostatectomy; WHO performance status 0-1; Adequate condition (ASA ≤ III) for general anesthesia and RP.
Exclusion: Any prior neoadjuvant, local or systemic treatment for PCa; Previous PLND or pelvic radiotherapy; Patients with a prior malignancy and treated with curative intention are eligible if all treatment of that malignancy was completed at least 2 years before registration and the patient has no evidence of disease at registration. Less than 2 years is acceptable for malignancies with low risk of recurrence and/or no late recurrence; Any other serious underlying medical, psychiatric, psychological, familial, or geographical; condition, which in the judgment of the investigator may interfere with the planned; ISUP grade group I PCa and cT1 or cT2 (MRI); cT4 (MRI) PCa; PSMA-PET: positive staging for local and distant metastasis; staging, treatment and follow-up, which affect patient compliance or place the patient at; high risk from treatment-related complications; Vulnerable men (participants incapable of judgment or participants under tutelage) will not be included in the study.